No black box warning on record for Yondelis

As of the latest FDA labeling reviewed, Yondelis (TRABECTEDIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Yondelis medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Neutropenic sepsis: Severe, and fatal, neutropenic sepsis may occur. Monitor neutrophil count during treatment. Withhold YONDELIS for neutrophil count < 1,500/mcL ( 2.4 , 5.1 ) Rhabdomyolysis: Rhabdomyolysis may occur. Monitor creatine phosphokinase (CPK) levels prior to each administration. Withhold YONDELIS for CPK more than 2.5 times the upper limit of normal. ( 2.4 ,

No black box warning on record for Yondelis

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Neutropenic sepsis: Severe, and fatal, neutropenic sepsis may occur. Monitor neutrophil count during treatment. Withhold YONDELIS for neutrophil count < 1,500/mcL ( 2.4 , 5.1 ) Rhabdomyolysis: Rhabdomyolysis may occur. Monitor creatine phosphokinase (CPK) levels prior to each administration. Withhold YONDELIS for CPK more than 2.5 times the upper limit of normal. ( 2.4 ,

Yondelis Black Box Warning

No black box warning on record for Yondelis

Other warnings & precautions

Yondelis Black Box Warning

No black box warning on record for Yondelis

Other warnings & precautions